Tesamorelin / Ipamorelin Blend
Status
No approved product. Tesamorelin holds FDA-approved labeling as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. No approval exists for ipamorelin or for any combination product.
What it is
A blended secretagogue vial pairing tesamorelin with ipamorelin.
What published research measured
Pairs the one growth hormone secretagogue in this library with a full FDA approval behind it against a ghrelin receptor agonist with none. Tesamorelin's randomized evidence is specific and worth reading in its own entry: it reduced visceral adipose tissue in HIV-associated lipodystrophy, with IGF-1 elevation requiring monitoring. That evidence was generated with tesamorelin alone, in that population, at the studied dose. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time. Because tesamorelin's approved labeling includes IGF-1 monitoring, adding a second agent that independently raises growth hormone changes the exposure the monitoring guidance was written around.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.